Kura Oncology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kura Oncology, Inc. on November 6, 2018. The report discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
Material Changes
On November 6, 2018, the Board of Directors appointed Mary Szela as a Class III director. Her term expires at the 2020 annual meeting of stockholders. There are no reported material changes to the company's financial position or operations in this filing.
Compensation and Governance Details
- Annual Cash Retainer: $38,000 for service on the Board.
- Initial Option Grant: 30,000 shares vesting annually over three years.
- Additional Option Grant: 7,583 shares vesting in full on the one-year anniversary of the grant date.
- Future Grants: Automatic annual option grants of 13,000 shares on the date of each annual meeting, vesting in full one year later.
- Change in Control: All option grants vest in full upon a change in control.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional context on the appointment.
- Review the Company's Amended and Restated Non-Employee Director Compensation Policy for standard terms applicable to other directors.
- Confirm the impact of the new director appointment on the composition of Board committees.